Biotech IPO window is opening but big pharma M&A still leaders, top bankers say
Biopharma dealmaking is driven by pressure to top up drug pipelines ahead of major patent expirations later this decade.
AI brief
Pulse reads the full article- What happened
- Why it matters
- What to watch
Sign in to get the AI brief. Pulse explains what happened, why it matters, what to watch and who's exposed. Free for members.
Sign in to read the brief